D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| 1 |
Pfizer
PFE
|
+$439M |
| 2 |
AbbVie
ABBV
|
+$401M |
| 3 |
Johnson & Johnson
JNJ
|
+$308M |
| 4 |
Gilead Sciences
GILD
|
+$261M |
| 5 |
Mercado Libre
MELI
|
+$259M |
Top Sells
| 1 |
Booking.com
BKNG
|
+$391M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$390M |
| 3 |
Citigroup
C
|
+$315M |
| 4 |
PayPal
PYPL
|
+$282M |
| 5 |
SHPG
Shire pic
SHPG
|
+$276M |
Sector Composition
| 1 | Technology | 20.75% |
| 2 | Consumer Discretionary | 16.79% |
| 3 | Healthcare | 16.62% |
| 4 | Financials | 9.01% |
| 5 | Industrials | 8.17% |